MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Accumulating evidence indicates that inflammation is prominent both in the blood and central
nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic
inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing
on the experience from a previous clinical trial with thalidomide, here, the investigators
hypothesize that modulating both systemic and CNS inflammation via the pleiotropic
immunomodulator lenalidomide is a putative therapeutic intervention for AD if administered at
a proper time window during the course of the disease.